| Literature DB >> 34849768 |
Minjoung M Koo1,2, Ruth Swann1,2,3, Sean McPhail2, Gary A Abel4, Cristina Renzi1, Greg P Rubin5, Georgios Lyratzopoulos1,2.
Abstract
BACKGROUND: There is uncertainty regarding how pre-existing conditions (morbidities) may influence the primary care investigation and management of individuals subsequently diagnosed with cancer.Entities:
Keywords: cancer; chronic disease; diagnosis; multimorbidity; primary care; risk assessment
Mesh:
Year: 2022 PMID: 34849768 PMCID: PMC9295610 DOI: 10.1093/fampra/cmab139
Source DB: PubMed Journal: Fam Pract ISSN: 0263-2136 Impact factor: 2.290
Descriptive statistics and logistic regression examining distribution of the primary care interval (PCI) and diagnostic interval (DI) and likelihood of a PCI >28 days and DI >60 days, by NCDA morbidity count and Charlson scores among 11,716 patients diagnosed with cancer in England in 2014.
|
| Centiles of the PCI/DI (days) | PCI >28 days | Crude OR for PCI >28 days or DI >60 days | Adjusted OR | Adjusted OR | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 10th | 25th | 50th | 75th | 90th |
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||
| Primary care interval | ||||||||||
| All patients | 9,402 | 0 | 0 | 5 | 27 | 77 | 2,246 (24%) | — | — | — |
| No. of NCDA morbidities | 0.001 | 0.073 | 0.102 | 0.369 | ||||||
| 0 morbidities | 2,342 | 0 | 0 | 3 | 23 | 77 | 518 (22%) | Ref | Ref | Ref |
| 1 morbidity | 2,922 | 0 | 0 | 5 | 28 | 82 | 716 (25%) | 1.14 (>1.00–1.30) | 1.13 (0.99–1.29) | 1.08 (0.94–1.24) |
| 2 morbidities | 2,274 | 0 | 0 | 5 | 27 | 66 | 539 (24%) | 1.09 (0.95–1.25) | 1.09 (0.94–1.27) | 1.06 (0.91–1.24) |
| 3+ morbidities | 1,864 | 0 | 0 | 5 | 29 | 84 | 473 (25%) | 1.20 (1.04–1.38) | 1.21 (1.04–1.42) | 1.16 (0.98–1.36) |
| Charlson score | 0.947 | 0.627 | 0.590 | 0.490 | ||||||
| 0 | 6,872 | 0 | 0 | 5 | 27 | 78 | 1,646 (24%) | Ref | Ref | Ref |
| 1 | 1,265 | 0 | 0 | 5 | 25 | 73 | 288 (23%) | 0.94 (0.81–1.08) | 0.92 (0.80–1.07) | 0.90 (0.78–1.05) |
| 2 | 669 | 0 | 0 | 4 | 29 | 71 | 170 (25%) | 1.08 (0.90–1.30) | 1.07 (0.89–1.29) | 1.06 (0.87–1.28) |
| 3+ | 596 | 0 | 0 | 6 | 27.5 | 67 | 142 (24%) | 0.99 (0.82–1.21) | 0.97 (0.80–1.19) | 0.96 (0.78–1.18) |
| Diagnostic interval | ||||||||||
| All patients | 10,236 | 10 | 18 | 42 | 91 | 190 | 3,831 (37%) | — | — | — |
| No. of NCDA morbidities | <0.001 | <0.001 | 0.001 | 0.004 | ||||||
| 0 morbidities | 2,476 | 9 | 15 | 38 | 82 | 177 | 861 (35%) | Ref | Ref | Ref |
| 1 morbidity | 3,171 | 10 | 19 | 44 | 93 | 195 | 1,216 (38%) | 1.17 (1.05–1.30) | 1.15 (1.02–1.29) | 1.11 (0.98–1.25) |
| 2 morbidities | 2,485 | 10 | 18 | 42 | 85 | 182 | 902 (36%) | 1.07 (0.95–1.20) | 1.06 (0.93–1.20) | 1.04 (0.91–1.19) |
| 3+ morbidities | 2,104 | 10 | 20 | 47 | 100 | 209 | 852 (40%) | 1.28 (1.13–1.44) | 1.29 (1.13–1.48) | 1.26 (1.10–1.45) |
| Charlson score | 0.016 | 0.044 | 0.092 | 0.055 | ||||||
| 0 | 7,404 | 10 | 18 | 42 | 87 | 181 | 2,721 (37%) | Ref | Ref | Ref |
| 1 | 1,408 | 9 | 18 | 42.5 | 95.5 | 209 | 530 (38%) | 1.04 (0.92–1.17) | 1.03 (0.91–1.16) | 1.02 (0.90–1.15) |
| 2 | 747 | 10 | 20 | 47 | 107 | 212 | 305 (41%) | 1.19 (1.02–1.38) | 1.17 (>1.00–1.37) | 1.19 (1.01–1.40) |
| 3+ | 677 | 10 | 19 | 46 | 106 | 213 | 275 (41%) | 1.18 (>1.00–1.38) | 1.16 (0.99–1.37) | 1.19 (>1.00–1.41) |
aTotal n = 9,402, 80% of patients had complete information on the PCI and n = 10,236, 87% of patients had complete information on the DI.
bKruskal–Wallis test P value at 50th centile.
cWald test for overall significance.
dModel including measure of morbidity, sex, age, ethnicity, and IMD.
eModel including measure of morbidity, sex, age, ethnicity, IMD, and cancer.
Descriptive statistics and logistic regression examining proportion and likelihood of having 3 or more pre-referral consultations in primary care by NCDA morbidity count and Charlson scores among 11,716 patients diagnosed with cancer in England in 2014.
|
| Three or more consultations | Crude OR for 3 or more consultations | Adjusted OR | Adjusted OR | |
|---|---|---|---|---|---|
| All patients | 11,473 | 2,837 (25%) | — | — | — |
| No. of NCDA morbidities | <0.001 | <0.001 | 0.010 | ||
| 0 morbidities | 2,839 | 599 (21%) | Ref | Ref | Ref |
| 1 morbidity | 3,554 | 880 (25%) | 1.23 (1.09–1.38) | 1.11 (0.98–1.25) | 1.03 (0.91–1.17) |
| 2 morbidities | 2,760 | 675 (24%) | 1.21 (1.07–1.37) | 1.04 (0.91–1.19) | 0.98 (0.85–1.13) |
| 3+ morbidities | 2,320 | 683 (29%) | 1.56 (1.37–1.77) | 1.31 (1.14–1.51) | 1.21 (1.05–1.40) |
| Charlson score | 0.05 | 0.896 | 0.982 | ||
| 0 | 8,298 | 1,997 (24%) | Ref | Ref | Ref |
| 1 | 1,561 | 405 (26%) | 1.11 (0.98–1.25) | 1.03 (0.91–1.17) | 0.98 (0.86–1.12) |
| 2 | 844 | 224 (27%) | 1.14 (0.97–1.34) | 1.04 (0.89–1.23) | 0.98 (0.83–1.16) |
| 3+ | 770 | 211 (27%) | 1.19 (1.01–1.41) | 1.05 (0.88–1.24) | 0.97 (0.82–1.16) |
aTotal n = 11,473, 98% of patients had complete information on number of pre-referral consultations.
bWald test for overall significance.
cModel including measure of morbidity, sex, age, ethnicity, and IMD.
dModel including measure of morbidity, sex, age, ethnicity, IMD, and cancer.
Descriptive statistics and logistic regression examining proportion and likelihood of having 1 or more primary care-led investigations by NCDA morbidity count and Charlson scores among 11,716 patients diagnosed with cancer in England in 2014.
|
| At least 1 investigation | Crude OR for at least 1 investigation | Adjusted OR | Adjusted OR | |
|---|---|---|---|---|---|
| Total | 11,230 | 6,777 (60%) | — | — | — |
| No. of NCDA morbidities | <0.001 | 0.914 | 0.365 | ||
| 0 morbidities | 2,762 | 1,544 (56%) | Ref | Ref | Ref |
| 1 morbidity | 3,487 | 2,128 (61%) | 1.24 (1.12–1.37) | 1.01 (0.90–1.12) | 0.91 (0.80–1.04) |
| 2 morbidities | 2,703 | 1,678 (62%) | 1.29 (1.16–1.44) | 0.97 (0.86–1.10) | 0.89 (0.77–1.03) |
| 3+ morbidities | 2,278 | 1,427 (63%) | 1.32 (1.18–1.48) | 0.97 (0.85–1.11) | 0.88 (0.76–1.03) |
| Charlson score | 0.630 | 0.004 | <0.001 | ||
| 0 | 8,102 | 4,886 (60%) | Ref | Ref | Ref |
| 1 | 1,541 | 917 (60%) | 0.97 (0.87–1.08) | 0.84 (0.75–0.95) | 0.74 (0.65–0.85) |
| 2 | 832 | 518 (62%) | 1.09 (0.94–1.26) | 0.93 (0.80–1.08) | 0.87 (0.73–1.04) |
| 3+ | 755 | 456 (60%) | >1.00 (0.86–1.17) | 0.80 (0.68–0.94) | 0.72 (0.60–0.86) |
aTotal n = 11,230, 96% of patients had complete information on investigations.
bWald test for overall significance.
cModel including measure of morbidity, sex, age, ethnicity, and IMD.
dModel including measure of morbidity, sex, age, ethnicity, IMD, and cancer.
Descriptive statistics and logistic regression examining referral type and likelihood of emergency referral by NCDA morbidity count and Charlson scores among 11,716 patients diagnosed with cancer in England in 2014.
| Total | Referral type | ||||||
|---|---|---|---|---|---|---|---|
| 2WW | Non-2WW | Emergency | Crude OR for emergency referral | Adj OR | Adj OR | ||
|
|
|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||
| Total | 10,703 | 7,785 (73%) | 1,928 (18%) | 990 (9%) | — | — | — |
| No. of NCDA morbidities | <0.001 | <0.001 | <0.001 | ||||
| 0 morbidities | 2,686 | 2,001 (74%) | 518 (19%) | 167 (6%) | Ref | Ref | Ref |
| 1 morbidity | 3,346 | 2,436 (73%) | 626 (19%) | 284 (8%) | 1.40 (1.15–1.71) | 1.24 (1.01–1.53) | 1.14 (0.92–1.42) |
| 2 morbidities | 2,550 | 1,873 (73%) | 419 (16%) | 258 (10%) | 1.70 (1.39–2.08) | 1.36 (1.09–1.69) | 1.28 (1.02–1.61) |
| 3+ morbidities | 2,121 | 1,475 (70%) | 365 (17%) | 281 (13%) | 2.30 (1.88–2.82) | 1.72 (1.37–2.15) | 1.60 (1.26–2.02) |
| Charlson score | <0.001 | <0.001 | <0.001 | ||||
| 0 | 7,786 | 5,796 (74%) | 1,378 (18%) | 612 (8%) | Ref | Ref | Ref |
| 1 | 1,469 | 1,005 (68%) | 282 (19%) | 182 (12%) | 1.66 (1.39–1.98) | 1.48 (1.24–1.77) | 1.41 (1.16–1.70) |
| 2 | 773 | 535 (69%) | 150 (19%) | 88 (11%) | 1.51 (1.19–1.91) | 1.30 (1.02–1.66) | 1.21 (0.94–1.56) |
| 3+ | 675 | 449 (67%) | 118 (17%) | 108 (16%) | 2.23 (1.79–2.79) | 1.80 (1.43–2.26) | 1.61 (1.26–2.06) |
aTotal n = 10,703. 2WW = 2-week-wait urgent referrals for suspected cancer; non-2WW includes routine, urgent non-cancer, and private referrals; emergency includes emergency referrals; 1,013 (9%) individuals whose referrals were categorized as patient self-referrals to A&E, “other,” “screen-detected,” and “not known” were excluded.
bWald test for overall significance.
cModel including measure of morbidity, sex, age, ethnicity, and IMD.
dModel including measure of morbidity, sex, age, ethnicity, IMD, and cancer. No melanoma patients were referred as an emergency and so these individuals (n = 665) were excluded from the model.
Fig. 1.Summary of associations between morbidity (defined as NCDA conditions and Charlson scores) and measures of the diagnostic process in primary care among 11,716 cancer patients.